OCTANINE F 500 IU

Maa: Israel

Kieli: englanti

Lähde: Ministry of Health

Osta se nyt

Valmisteyhteenveto Valmisteyhteenveto (SPC)
23-08-2017

Aktiivinen ainesosa:

FACTOR IX

Saatavilla:

DOVER MEDICAL & SCIENTIFIC EQUIPMENT LTD, ISRAEL

ATC-koodi:

B02BD04

Lääkemuoto:

POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Koostumus:

FACTOR IX 100 IU/ML

Antoreitti:

I.V

Prescription tyyppi:

Required

Valmistaja:

OCTAPHARMA AG, SWITZERLAND

Terapeuttinen ryhmä:

COAGULATION FACTOR IX

Terapeuttinen alue:

COAGULATION FACTOR IX

Käyttöaiheet:

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

Valtuutus päivämäärä:

2018-06-30

Valmisteyhteenveto

                                page 1/11
_octanine-spc-clean_copy-minor_changes-1.2017_
_ _
The format of this leaflet has been defined by the MOH and its content
has been
checked and approved
7.2013
INSTRUCTION FOR USE
(SUMMARY OF PRODUCT CHARACTERISTICS)
1
NAME OF THE MEDICINAL PRODUCT
OCTANINE F 500 IU
, 500 IU powder and solvent for solution for injection
OCTANINE F 1000 IU
, 1000 IU powder and solvent for solution for injection
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
•
OCTANINE F 500 IU is presented as a powder and solvent for solution
for injection
containing nominally 500 IU human coagulation factor IX per vial.
The product contains approximately 100 IU/ml human coagulation factor
IX when
reconstituted with 5 ml water for injections (Ph.Eur.).
•
OCTANINE F 1000 IU is presented as a powder and solvent for solution
for injection
containing nominally 1000 IU human coagulation factor IX per vial.
The product contains approximately 100 IU/ml human coagulation factor
IX when
reconstituted with 10 ml water for injections (Ph.Eur.).
OCTANINE F is produced from plasma of human donors.
The potency (IU) is determined using the European Pharmacopoeia one
stage clotting test, in
comparison with an international standard from the World Health
Organisation (WHO). The
specific activity of OCTANINE F
is approximately
≥
100 IU/mg protein.
This medicinal product contains up to 3 mmol (or 69 mg) sodium for 1
vial OCTANINE F
500 IU and up to 6 mmol (or 138 mg) sodium for 1 vial OCTANINE F 1000
IU per dose. To
be taken into consideration by patients on a controlled sodium diet.
For a full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Powder and solvent for solution for injection.
The powder is white or pale yellow also appearing as a friable solid.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment and prophylaxis of bleeding in patients with haemophilia B
(congenital factor IX
deficiency).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
page 2/11
_octanine-spc-clean_copy-minor_changes-1.2017_
_ _
Treatment should be initiated under
                                
                                Lue koko asiakirja
                                
                            

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia